Milks Material - BMS

Card Set Information

Author:
DrJBlack
ID:
121102
Filename:
Milks Material - BMS
Updated:
2011-12-05 23:11:25
Tags:
BMS
Folders:

Description:
MABs and Other Material
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user DrJBlack on FreezingBlue Flashcards. What would you like to do?


  1. CD2
    T-Cell Antigen common to all T-cells; (also NK cells)
  2. CD3
    T-cell Antigen complexed with the alpha and beta chains of the TCR; thymocytes, peripheral T cells
  3. CD4
    • T-cell Antigent that's a helper/inducer T-Cell Class II MHC coreceptor
    • Helper subset of peripheral T cells, single positive medullary thymocytes, and CD4/CD8 double positive thymocytes
  4. CD8
    • T-cell Antigen that's cytotoxic/suppressor T-cell Class I MHC coreceptor
    • cytotoxic subset of peripheral T cells, single positive medullary thymocytes, double positive coritcal thyocytes, and some NK cells
  5. TCR
    T-cell Antigen and a T-cell receptor; antigen binding (single paratope)
  6. CD19
    • B-cell antigent that deals with signal transduction; (B-cell co-receptor
    • NOT expressed on plasma cells
    • marrow pre-B cells and mature B cells
  7. CD20
    • B-cell antigen characteristic surface antigen of normal and malignant B-cells
    • marrow pre-B cells after CD19 and mature B cells
    • NOT plasma cells
  8. CD21
    B-cell antigen that's complement C3b receptor; (B-cell co-receptor); EBV "receptor;" present on mature B cells and follicular dendritic cells
  9. CD32
    B-cell antigen Fc receptor for IgG
  10. CD81
    B-cell antigen that's TAPA-1; (B-cell co-receptor)
  11. sIgM
    B-cell antigen (monomeric); antigen binding (2 identical paratopes)
  12. CD11c
    • primarily monocyte/macrophage associated
    • granulocytes, monocytes, macrophages; also expressed by hairy cell leukemias
  13. CD16
    NK cells and granulocytes
  14. CD56
    NK cels and subset of T cells
  15. Immediate (type 1) hypersensitivity
    • Prototype Disorder: anaphylaxis; allergies; bronchial asthma (atopic forms)
    • Immune Mechanisms: production of IgE antibody -> immediate release of vasoactive amines and other mediators from mast cells; recruitment of inflammatory cells (late phase reaction)
    • Pathologic Lesions: vascular dilation, edema, smooth muscle contraction, mucus production, inflammation
  16. Antibody-mediated (type 2) hypersensitivity
    • activate complement
    • Prototype Disorder: hemolytic anemia; Goodpasture syndrome
    • Immune Mechanism: Production of IgG, IgM -> binds to antigen on target cell/tissue -> phagocytosis or lysis of target cell by activated complement or Fc receptors; recruitment of leukocytes
    • Pathologic Lesions: cell lysis; inflammation
  17. Immune complex-mediated (type 3) hypersensitivity
    • circulating antibdoies binding to circulating antigens
    • Prototype Disorder: systemic lupus erythematosus; some forms of glomerulonephritis; serum sickness; Arthus reaction
    • Immune Mechanisms: Deposition of antigen-antibody complexes -> complement activation -> recruitment of leukocytes by complement products and Fc receptors -> release of enzymes and other toxic molecules
    • Pathologic Lesions: necrotizing vasculitis (fibrinoid necorsis); inflammation
  18. Cell-mediated (type 4) hypersensitivity
    • TH1 cells
    • Prototype Disorder: contact dermatitis; multiple sclerosis; type I, diabetes; translpant rejection; tuberculosis
    • Immune Mechanism: Activated T lymphocytes -> release of cytokines and macrophage activation; T-cell mediated cytotoxicity
    • Pathologic Lesions: Perivascular cellular infiltrates; edema; cell destruction; granuloma formation
  19. Autoimmune hemolytic anemia
    • Target Antigen: erythrocyte membrane proteins (Rh blood group antigens, I antigen)
    • Mechanisms of Disease: opsonization and phagocytosis of erythrocytes
    • Clinicopathologic Manifestations: hemolysis, anemia
  20. Autoimmune thrombocytopenic purpura
    • Target Antigen: platelet membrane protiens (gp2b:gp3a integrin)
    • Mechanisms of Disease: opsonization and phagocytosis of platelets
    • Clinicopathologic Manifestations: bleeding
  21. Goodpasture Syndrome
    • Target Antigen: noncollagenous protein in basement membranes of kidney glomeruli and lung alveoli
    • Mechanisms of Disease: complement- and Fc receptor- mediated inflammation
    • Clinicopathologic Manifestations: nephritis, lung hemorrhage
  22. Myasthenia gravis
    • Target Antigen: acetylcholine receptor
    • Mechanisms of Disease: antibody inhibits acetylcholine binding, down-modulates receptors
    • Clincopathologic Manifestations: muscle weakness, paralysis
  23. Graves disease (hyperthyroidism)
    • Target Antigen: TSH receptor
    • Mechanisms of Disease: antibody-mediated stimulation of TSH receptors
    • Clinicopathologic Manifestations: hyperthyroidism
  24. Systemic lupus erythematosus
    • Antigen involved: DNA, nuceloproteins, others
    • Clincopathologic Manifestations: nephritis, arthritis, vasculitis
  25. Poststreptococcal glomerulonephritis
    • took awhile to generate antibodies at the damage skin
    • Antigen Involved: stretococcal cell wall antigen(s); may be "planted" in glomerular basement membrane
    • Clinicopathologic Manifestations: nephritis
  26. Arthus Reaction
    • Antigent Involved: various foreign proteins - local where antigens stay
    • Clinicopathologic Manifestations: cutaneous vasculitis
  27. suffix - mab
    monoclonal antibody
  28. infix immediately preceeding the suffix identifies ____ of the antibody
    species source
  29. u
    human
  30. o
    murine (mouse)
  31. a
    rat
  32. i
    primate
  33. xi
    chimeric- mostly human, but some mouse
  34. zu
    humanized - ~95% human, remaining mouse
  35. infix preceding the species infix designates the _____
    target
  36. vi(r)
    viral
  37. li(m)
    immune system
  38. ki(n)
    interleukins
  39. ci(r)
    circulatory
  40. tu(m)
    tumor
  41. muromonab - CD3
    • Ligand/Target: CD3 on T-lymphocytes
    • Indication: acute graft rejection
  42. abciximab
    • Ligand/Taget: glycoprotein IIb/IIIa receptors on platelets
    • Indication: prevent reocclusion of coronary arteries following PTCA
  43. rituximab
    • Ligand/Target: CD20 on B lymphocytes
    • Indication: non-Hodkin's lymphoma
    • chronic lymphotcyic leukemia
    • rheumatoid arthritis
    • Wegener's Granulomatosis (WG) and Microscopic Polyangiitis
  44. ibritumomab tiuxetan
    • Ligand/Target: CD20 on B lymphocytes
    • Indication: non-Hodgkin's lymphoma
  45. tositumomab
    • Ligand: CD20 on B lymphocytes
    • Indication: non-Hodgkin's lymphoma
  46. ofatumumab
    • Ligand: CD20 on B-lymphocytes
    • Indication: chronic lympocytic leukemia
  47. brentuximab vedotin
    • CD30 on malignant lymphocytes
    • Indications: Hodgkin lymphoma
    • anaplastic large cell lymphoma (ALCL)
  48. alemtuzumab
    • Ligand: CD52 on leukocytes
    • Indication: B-cell chronic lymphocytic leukemia
  49. ipilimumab
    • Ligand: CTLA-4 on T-lymphocytes
    • Indication: malignant melanoma
  50. trastuzumab
    • Herceptin
    • Ligand: Human Epidermal growth factor Receptor (HER2)
    • Indication: metastatic breast cancer
  51. cetuximab
    • Erbitux
    • Ligand: Epidermal Growth Factor Receptor (EGFR-1; HER-1; c-Erb-1)
    • Indication: metastatic colorectal carcinoma
    • head and neck squamous cell carcinoma
  52. panitumumab
    • Ligand: Epidermal Growth Factor Receptor (EGFR-1; HER-1; c-Erb-1)
    • Indication: colorectal carcinoma
  53. bevacizumab
    • Ligand: Vascular Endothelial Growth Factor (VEGF)
    • Indication: metastatic colorectal carcinoma
    • glioblastoma
    • metastatic renal cell carcinoma
    • nonsquamous non-small lung cancer
  54. ranibizumab
    • Ligand: Vascular Endothelial Growth Factor (VEGF)
    • Indication: neovascular ("wet") age related macular degeneration (AMD)
  55. basiliximab
    • Ligand: binds to alpha-subunit (CD25) of IL-2 receptors
    • Indication: immunosuppressant
  56. daclizumab
    • Ligand: binds to alpha-subunit (Tac) of IL-2 receptors
    • Indication: immunosuppressant
  57. belimumab
    • Ligand: binds to B-lymphocyte stimulator
    • Indication: systemic lupus erythematosus
  58. infliximab
    • Ligand: TNF-alpha
    • Indication: rheumatoid arthritis
    • psoriatic arthritis
    • plaque psoriasis
    • ankylosing spondylitis
    • ulcerative colitis
    • Crohn's disease
  59. adalimumab
    • Ligand: TNF-alpha
    • Indication: rheumatoid arthritis
    • juvenile idiopathic arthritis
    • psoriatic arthritis
    • ankylosing spondylitis
    • Crohn's Disease
    • plaque psoriasis
  60. golimumab
    • Ligand: TNF-alpha
    • Indication: rheumatoid arthritis
    • psoriatic arthritis
    • ankylosing spondylitis
  61. certolizumab pegol
    • Ligand: TNF-alpha
    • Indication: Crohn's Disease
  62. toclizumab
    • Ligand: IL-6 receptor
    • Indication: rheumatoid arthritis
  63. ustekinumab
    • Ligand: p40 protein subunit of IL-12 and IL-23
    • Indication: plaque psoriasis
  64. omalizumab
    • Ligand: IgE
    • Indication: asthmas
  65. palivizumab
    • Ligand: respiratory syncytical virus
    • Indication: prophylaxis against RSV infection
  66. natalizumab
    • Ligand: alpha 4 subunit of alpha-4-beta-1 and alpha-4-beta-7 integrins expressed on the surface of leukocytes
    • Indication: multiple sclerosis
  67. eculizumab
    • Ligand: complement protein C5
    • Indication: paroxysmal nocturnal hemoglobinuria (PNH)
  68. efalizumab
    • Ligand: CD11a, the alpha-subunit of leukocyte function antigen-1 (LFA-1)
    • Indication: plaque psoriasis
  69. canakinumab
    • Ligand: IL-1beta
    • Indication: Cryopyrin-associated Periodic Syndromes (CAPS)
  70. denosumab
    • Ligand: RANKL (receptor activator of nuclear factor kappa B Ligand)
    • Indication: bone, osteoporosis
    • prevention of skeletal-related events in patients with bone metastases from solid tumors
  71. etanercept
    • Ligand: TNF-alpha
    • Indication: rheumatoid arthritis
    • polyarticular-course juevenile rheumatoid arthritis
    • ankylosing spnodylitis
    • plaque psoriasis
    • psoriatic arthritis
  72. abatacept
    • Ligand: CD80 and CD86 (B7.1 and B7.2)
    • Indication: rheumatoid arthritis
  73. belatacept
    • Ligand: CD80 and CD86 (B7.1 and B7.2)
    • Indication: renal transplantation
  74. alefacept
    • Ligand: CD2 on T-lymphocytes
    • Indication: plaque psoriasis
  75. rilonacept
    • Ligand: IL-1beta
    • Indication: Cryopyrin-Associated Periodic Syndromes (CAPS)
  76. aflibercept
    • Ligand: VEGF
    • Indication: neovascular ("wet") age-related macular degeneration (AMD)
  77. gemtuzumab ozogamicin
    • Ligand: CD33 on myeloid colony-forming cells
    • Indication: acute myeloid leukemia (AML)

What would you like to do?

Home > Flashcards > Print Preview